Fibroblast Growth Factor 23 is a Predictor of Aortic Artery Calcification in Maintenance Hemodialysis Patients

Background: Our study aimed to investigate the factors associated with elevated plasma FGF23 (cFGF23) levels in maintenance hemodialysis (MHD) patients and to determine whether plasma FGF23 level is related to aortic artery calcification (AAC). Methods: This study included 120 MHD patients and 20 controls. The FGF23 level was measured using a C-terminal assay and AAC was detected by a lateral lumbar X-ray plain. Results: Plasma FGF23 levels were significantly higher among dialysis patients compared to controls: FGF23 level of 27691.42 ± 55646.41 RU/mL in MHD patients versus 49.89 ± 23.94 RU/mL in health people. Significant correlations were observed between FGF23 levels and vintage, intact parathyroid hormone (iPTH), serum phosphate, total calcium, 25(OH)D, urea nitrogen (BUN), and serum creatinine (SCR). Stepwise multiple regression analysis showed that the independent parameters associated with FGF23 level were serum phosphate, total calcium, parathyroid hormone (PTH), SCR, and prealbumin. There were 73 patients (60.83%) with visible calcification in the abdominal aorta. Bivariate analysis showed that AAC score correlated with FGF23, phosphate, total calcium, vintage, age, and diastolic blood pressure. Forward logistic analysis showed that the independent parameters associated with AAC were age, total protein, and Lg FGF23. Conclusion: Plasma FGF23 level is significant increased in hemodialysis patients and is independently associated with AAC.

[1]  L. Kuller,et al.  The prevalence of aortic calcification in Japanese compared to white and Japanese-American middle-aged men is confounded by the amount of cigarette smoking. , 2013, International journal of cardiology.

[2]  M. Wolf,et al.  Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[3]  A. Go,et al.  FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.

[4]  D. Fliser,et al.  The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. , 2011, European heart journal.

[5]  S. Booth,et al.  FGF‐23 is associated with cardiac troponin T and mortality in hemodialysis patients , 2011, Hemodialysis international. International Symposium on Home Hemodialysis.

[6]  A. Ortiz,et al.  Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  Jiang He,et al.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. , 2011, JAMA.

[8]  Huiliang Xie,et al.  Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. , 2011, Kidney international.

[9]  K. Polkinghorne,et al.  Lateral lumbar X‐ray assessment of abdominal aortic calcification in Australian haemodialysis patients , 2011, Nephrology.

[10]  S. Draibe,et al.  Fibroblast Growth Factor 23 in Chronic Kidney Disease: Bridging the Gap between Bone Mineral Metabolism and Left Ventricular Hypertrophy , 2010, Blood Purification.

[11]  M. Shlipak,et al.  Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  C. Chazot,et al.  High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  C. Chazot,et al.  Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  B. Wikström,et al.  Abdominal aortic calcification in dialysis patients: results of the CORD study , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  G. Kantarci,et al.  Klotho: an antiaging protein involved in mineral and vitamin D metabolism. , 2007, Kidney international.

[16]  M. Inaba,et al.  Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  K. Okawa,et al.  Klotho converts canonical FGF receptor into a specific receptor for FGF23 , 2006, Nature.

[18]  P. Raggi,et al.  Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients. , 2006, Kidney international.

[19]  M. Inaba,et al.  Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients , 2006, Osteoporosis International.

[20]  T. Yamashita,et al.  Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. , 2006, The Journal of clinical endocrinology and metabolism.

[21]  Hang Lee,et al.  Regulation of C‐Terminal and Intact FGF‐23 by Dietary Phosphate in Men and Women , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  T. Shigematsu,et al.  Sevelamer Hydrochloride and Calcium Bicarbonate Reduce Serum Fibroblast Growth Factor 23 Levels in Dialysis Patients , 2005, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[23]  M. Wolf,et al.  Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[24]  V. Andreucci,et al.  Coronary artery calcification in patients with CRF not undergoing dialysis. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  G. London,et al.  Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  S. Takeda,et al.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Kiel,et al.  New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. , 1997, Atherosclerosis.

[28]  S. Mundra,et al.  Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis , 2009 .

[29]  Y. Caliskan,et al.  Fibroblast Growth Factor-23 (fgf-23) Is Independently Correlated to Aortic Calcification in Haemodialysis Patients Department of Endocrinology and Association of Fgf-23 with Aortic Calcification 2679 , 2022 .